NCT06284317
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06284317 |
| Title | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients with Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung) |
| Acronym | ADOPT-lung |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | ETOP IBCSG Partners Foundation |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | NLD | ITA | IRL | GBR | FRA | EST | CHE | BEL | AUT | AUS |
CKB BOOST